Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study

•First-line crizotinib treatment is beneficial in Chinese patients with ROS1-positive advanced NSCLC.•Involvement of more than two metastatic organs was an independent factor associated with shorter PFS.•G2032R mutation in the ROS1 kinase domain was the most common mechanism of resistance to crizoti...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2020-09, Vol.147, p.130-136
Hauptverfasser:	Zheng, Jing, Cao, He, Li, Yuping, Rao, Chuangzhou, Zhang, Te, Luo, Jiayou, Lv, Dongqing, Zhu, Yanping, Zhou, Jianya, Zhou, Jianying
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics China Crizotinib Crizotinib - therapeutic use Effectiveness Female First-line treatment Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Male Middle Aged Non-small cell lung cancer Prognosis Prognostic factors Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - genetics Proto-Oncogene Proteins - genetics Resistance mechanisms Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!